![]() ![]() ![]()
EI Compendex Source List(2022年1月)
EI Compendex Source List(2020年1月)
EI Compendex Source List(2019年5月)
EI Compendex Source List(2018年9月)
EI Compendex Source List(2018年5月)
EI Compendex Source List(2018年1月)
中国科学引文数据库来源期刊列
CSSCI(2017-2018)及扩展期刊目录
2017年4月7日EI检索目录(最新)
2017年3月EI检索目录
最新公布北大中文核心期刊目录
SCI期刊(含影响因子)
![]() ![]() ![]()
论文范文
1. Introduction Metabolic Syndrome (MetS) arises from systemic metabolic perturbations characterized by dyslipidemia and central obesity [1]. MetS is associated with an increased risk of developing cardiovascular disease, liver fibrosis and cancer, colon cancer, and breast cancer [2–5]. MetS characteristics are highly prevalent among individuals with nonalcoholic fatty liver disease (NAFLD), particularly those who are obese (Body Mass Index or BMI ≥ 30) or have insulin resistance [6]. A meta-analysis of studies demonstrated that NAFLD patients had increased intestinal permeability compared to healthy controls. Intestinal inflammation and upregulation of tumor necrosis factor-α (TNFα), common in obese individuals with MetS and NAFLD, are also associated with intestinal leakage [7]. Pathophysiology of MetS and NAFLD has been attributed to changes in intestinal epithelial barriers, leading to altered intestinal permeability and translocation of microbes or microbial products, such as lipopolysaccharide (LPS) [8, 9]. Structural proteins, such as ZO-1 and Occludin, compose a cytoskeletal-supported cell junction network that maintains transport across the intestinal epithelial barrier and regulates permeability during normal physiology [10, 11]. Expression and localization of these structural proteins are known to be regulated by certain microRNAs (miRs), such as miR-142-3p, which regulates Rac1 [12]. We previously reported altered expression of miR-142-3p, miR-18b, and miR-890 in a cohort of patients with fatty liver (FL), who also met established criteria for MetS as defined by the International Diabetes Federation [1]. Also altered in this cohort were the expressions of mRNAs related to hepatocellular carcinoma progression pathways of adhesion, invasion, and metastasis [13]. Thus, these three miRs (hsa-miR-142-3p, hsa-miR-18b, and hsa-miR-890) may be indicators of epithelial barrier functional modifications in metabolically related MetS-FL. ![]() |
|